Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Recruiting

Phase 2

MyeloMATCHTesting the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05554406

Conditions

Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm

Acute Myeloid Leukemia Post Cytotoxic Therapy

Acute Myeloid Leukemia, Myelodysplasia-Related

Eligibility Criteria

Sex: All

Age: 18 - 59

Healthy Volunteers: Not accepted

Interventions

Azacitidine

Biospecimen Collection

Bone Marrow Aspiration

Cytarabine

Daunorubicin Hydrochloride

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-19. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-25.